In short
Clinical trials are studying Lu Ag09222 in adults with migraine who did not get enough help from earlier preventive treatments. The main goal is to check how well it works for migraine prevention and to gather safety and efficacy data in a Phase 2 study.
Key points
- Clinical trials are studying Lu Ag09222 for migraine prevention in adults with migraine who were not helped enough by earlier preventive treatments. The available trial is a Phase 2 interventional study and is authorised. It plans to include 1,036 people. The main measure is the change from baseline in the Monthly Migraine Diary over Weeks 1 to 12. The study compares Lu Ag09222 with a placebo that is made to match the study medicine. The focus is on how well the treatment works for preventing migraine.
Trial overview
The available study for Lu Ag09222 is a Phase 2 clinical trial in adults with migraine. It is a study of prevention, which means the researchers want to see whether the treatment can help reduce migraines over time.
The trial status is Authorised, and the study type is interventional, meaning researchers give a study treatment and then measure the results.
Who can join the study
This trial is for adults with migraine who have not been helped by prior preventative treatments. In simple terms, the study is looking at people whose earlier medicine did not control migraine well enough.
The trial data do not list more detailed entry rules, so the main known target group is adults with migraine and a history of poor response to prevention treatment.
What is being measured
The main outcome is the change from baseline in Monthly Migraine Diary during Weeks 1-12. Baseline means the starting point before treatment begins, so the study is checking how much migraine patterns change after treatment starts.
The brief summary says the study is designed to evaluate the efficacy of Lu Ag09222 for migraine prevention. Efficacy means how well the treatment works for the condition being studied.
Study design and treatment groups
The interventions listed are Lu Ag09222 given subcutaneously and a placebo that matches the study medicine. Subcutaneous means given under the skin, and a placebo is a comparison treatment that does not contain the active study drug.
This kind of design helps researchers compare the study treatment with a control group, so they can better judge whether changes are due to Lu Ag09222 and not just chance.
Trial phase and size
The study is in Phase 2, which is an early-to-mid stage of testing where researchers look more closely at whether a treatment may work and continue to watch safety. The planned enrollment is 1036 participants, which means the study aims to include 1,036 people.
A study of this size can help researchers collect more reliable information about migraine prevention in the target population.
Key patient terms
Preventative treatment means medicine taken to reduce how often migraines happen. In this trial, participants are people who did not get enough help from earlier preventive treatment.
Monthly Migraine Diary is the record used to track migraine changes during the study. Weeks 1-12 is the time window used for the main result measure.
Interventional means the study gives a treatment and measures what happens afterward. Authorised means the trial has been approved to move forward.